Marinus Pharmaceuticals, Inc. to Post Q2 2024 Earnings of ($0.59) Per Share, Leerink Partnrs Forecasts (NASDAQ:MRNS)

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) – Leerink Partnrs lowered their Q2 2024 earnings per share estimates for shares of Marinus Pharmaceuticals in a research report issued on Wednesday, May 8th. Leerink Partnrs analyst M. Goodman now forecasts that the biopharmaceutical company will earn ($0.59) per share for the quarter, down from their prior estimate of ($0.48). The consensus estimate for Marinus Pharmaceuticals’ current full-year earnings is ($2.00) per share. Leerink Partnrs also issued estimates for Marinus Pharmaceuticals’ Q3 2024 earnings at ($0.37) EPS, Q4 2024 earnings at ($0.11) EPS, FY2024 earnings at ($1.75) EPS, FY2025 earnings at ($0.70) EPS, FY2026 earnings at ($0.10) EPS and FY2028 earnings at $0.70 EPS.

Marinus Pharmaceuticals (NASDAQ:MRNS) last released its quarterly earnings results on Tuesday, March 5th. The biopharmaceutical company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.10). Marinus Pharmaceuticals had a negative net margin of 513.80% and a negative return on equity of 518.13%. The business had revenue of $7.19 million for the quarter, compared to analyst estimates of $7.78 million. During the same period in the prior year, the business earned ($0.76) earnings per share.

Other equities research analysts also recently issued research reports about the company. Cantor Fitzgerald restated an “overweight” rating and set a $28.00 target price on shares of Marinus Pharmaceuticals in a research report on Wednesday, April 10th. Royal Bank of Canada restated a “sector perform” rating and set a $3.00 target price (down from $24.00) on shares of Marinus Pharmaceuticals in a research report on Monday, April 15th. Truist Financial lowered their price target on shares of Marinus Pharmaceuticals from $25.00 to $10.00 and set a “buy” rating for the company in a research report on Wednesday, April 17th. HC Wainwright cut their price objective on shares of Marinus Pharmaceuticals from $27.00 to $11.00 and set a “buy” rating on the stock in a report on Tuesday, May 7th. Finally, StockNews.com cut shares of Marinus Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, March 6th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, Marinus Pharmaceuticals presently has an average rating of “Hold” and an average target price of $13.79.

Marinus Pharmaceuticals Trading Down 0.7 %

MRNS stock opened at $1.34 on Monday. The business has a fifty day moving average price of $5.68 and a 200 day moving average price of $7.74. Marinus Pharmaceuticals has a fifty-two week low of $1.11 and a fifty-two week high of $11.26. The stock has a market capitalization of $73.61 million, a price-to-earnings ratio of -0.51 and a beta of 1.14. The company has a debt-to-equity ratio of 5.68, a current ratio of 3.07 and a quick ratio of 2.93.

Hedge Funds Weigh In On Marinus Pharmaceuticals

Institutional investors have recently modified their holdings of the business. Vanguard Group Inc. lifted its holdings in shares of Marinus Pharmaceuticals by 1.2% during the 3rd quarter. Vanguard Group Inc. now owns 2,577,475 shares of the biopharmaceutical company’s stock valued at $20,749,000 after purchasing an additional 31,233 shares in the last quarter. Schonfeld Strategic Advisors LLC raised its position in Marinus Pharmaceuticals by 69.5% in the 3rd quarter. Schonfeld Strategic Advisors LLC now owns 253,412 shares of the biopharmaceutical company’s stock valued at $2,040,000 after buying an additional 103,935 shares during the last quarter. Adage Capital Partners GP L.L.C. raised its position in Marinus Pharmaceuticals by 6.3% in the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 2,904,476 shares of the biopharmaceutical company’s stock valued at $23,381,000 after buying an additional 173,226 shares during the last quarter. Jennison Associates LLC raised its position in Marinus Pharmaceuticals by 58.4% in the 3rd quarter. Jennison Associates LLC now owns 2,955,343 shares of the biopharmaceutical company’s stock valued at $23,791,000 after buying an additional 1,089,913 shares during the last quarter. Finally, SG Americas Securities LLC acquired a new stake in Marinus Pharmaceuticals in the 4th quarter valued at approximately $134,000. Institutional investors own 98.80% of the company’s stock.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.